ReviewACS pharmacology & translational science2026
Exploring Galectin‑3 as an Emerging Frontier in Biomarker Research for Clinical Trials Approaching Cardiovascular Diseases.
Review in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Value of Serum Pentraxin 3 and Galectin-3 in Early Pregnancy for Gestational Diabetes Mellitus in Chinese Women.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research has consistently highlighted galectin-3 (Gal-3) as a leading biomarker candidate for cardiovascular and cerebrovascular disease. Within studies focused on atherosclerosis-related cardiovascular disease, Gal-3 has played a multifaceted role, from monitoring disease progression to predicting outcomes. This reanalysis highlights the association of Gal-3 with various clinical factors, pathophysiological processes, other biomarkers, and critical outcomes. To maximize the potential of Gal-3 in future research, a uniform methodology that ensures consistent and easily comparable results is essential. Furthermore, our results highlight the synergy between elevated Gal-3 levels and established diagnostic measures of heart failure (HF). In this review, we present a reanalysis that provides a seminal synthesis of clinical trials using Gal-3 as a measure or outcome measure and aims to both capture current understanding and pave the way for its increased clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.